LLY vs JNJ vs PFE Stock Comparison

Eli Lilly, Johnson & Johnson and Pfizer Prices as of Nov 13, 2026 Peers: Industry group
LLY ELI LILLY & Co
$1,445.40 +19.4% 1M +41.3% 1Y
Market cap
$1.28T
P/E
46.3x
Revenue (TTM)
$86.46B
Div. yield
–
Pharmaceuticals Healthcare
6 wins
JNJ Johnson & Johnson
$286.11 +12.7% 1M +46.5% 1Y
Market cap
$681.31B
P/E
42.3x
Revenue (TTM)
$99.34B
Div. yield
0.02%
Pharmaceuticals Healthcare
3 wins
PFE Pfizer Inc
$28.90 -1.1% 1M +12.1% 1Y
Market cap
$164.42B
P/E
40.8x
Revenue (TTM)
$63.63B
Div. yield
0.06%
Pharmaceuticals Healthcare
3 wins

Head to Head

12 decided of 12

Eli Lilly leads on 6 of the 12 questions below (Eli Lilly 6, Pfizer 3, Johnson & Johnson 3). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionLLYJNJPFELeader
Larger companyMarket capitalisation $1.28T $681.31B $164.42B LLY
Cheaper on earningsLower P/E, profitable companies only 46.3x 42.3x 40.8x PFE
Cheaper on forward earningsLower price / next fiscal year consensus EPS 43.1x 26.7x 9.8x PFE
Faster revenue growthRevenue growth, trailing twelve months +45.5% +7.8% +1.3% LLY
More profitableNet margin, trailing twelve months 31.9% 16.2% 6.3% LLY
Better return on capitalReturn on invested capital 30.9% 17.6% 12.3% LLY
Less leveragedLower net debt / EBITDA 1.2x 0.8x 1.9x JNJ
Higher dividend yieldTrailing dividend yield 0.00% 0.02% 0.06% PFE
Better 1-year returnPrice return, last 12 months +41.3% +46.5% +12.1% JNJ
Better 5-year returnAnnualised price return, 5 years +41.0%/yr +11.6%/yr -10.3%/yr LLY
Less volatileAnnualised volatility, 1 year 35.0% 21.2% 21.7% JNJ
Higher overall scoreMean of the five percentile scores vs peers 71/100 65/100 68/100 LLY

Percentile Scorecard

LLYJNJPFE

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisLLYJNJPFE
Valuation 76 #159 of 660 84 #104 of 660 95 #37 of 660
Growth 93 #45 of 619 34 #410 of 619 37 #392 of 619
Profitability 98 #11 of 595 94 #39 of 595 92 #50 of 595
Financial Health 26 #505 of 683 39 #416 of 683 25 #516 of 683
Shareholder Returns 64 #167 of 459 73 #123 of 459 91 #44 of 459
Overall 71 65 68
  • LLY ranked among 695 companies in Pharmaceuticals and Biotechnology
  • JNJ ranked among 695 companies in Pharmaceuticals and Biotechnology
  • PFE ranked among 695 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodLLYJNJPFESPY
1 month +19.4%+12.7%-1.1% -2.0%
3 months +22.5%+9.9%+7.9% -2.8%
6 months +43.8%+26.2%+14.1% +2.0%
Year to date +34.5%+38.3%+16.1% +10.6%
1 year +41.3%+46.5%+12.1% +12.2%
3 years +136.6%+93.8%-1.2% +68.1%
3 years, per year +33.3%+24.7%-0.4% +18.9%
5 years +456.7%+73.4%-41.9% +61.4%
5 years, per year +41.0%+11.6%-10.3% +10.1%
10 years +1,761.0%+141.5%-11.3% +248.5%
10 years, per year +34.0%+9.2%-1.2% +13.3%

Risk

MeasureLLYJNJPFESPY
Volatility, 1Y 35.0%21.2%21.7% 13.6%
Downside volatility, 1Y 30.0%20.1%21.9% 13.9%
Beta vs S&P 500, 1Y 0.30-0.090.26 1.00
Return / volatility, 1Y 1.182.190.56 0.90
Max drawdown, 5Y -34.8%-23.6%-64.8% -25.4%
From 52-week high 0.0%0.0%-6.1% -3.2%
52-week high $1,445.40$286.11$30.79 $779.14
52-week low $851.21$195.25$23.67 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleLLYJNJPFE
P/E now vs peer median 46.7xmedian 17.0x 42.8xmedian 17.0x 40.8xmedian 17.0x
P/S now vs peer median 15.7xmedian 8.4x 6.9xmedian 8.4x 2.6xmedian 8.4x
EV/EBITDA now vs peer median 38.0xmedian 14.6x 21.5xmedian 14.6x 8.2xmedian 14.6x
P/FCF now vs peer median 69.2xmedian 19.0x 33.5xmedian 19.0x 14.0xmedian 19.0x
P/B now vs peer median 33.8xmedian 2.0x 8.4xmedian 2.0x 1.8xmedian 2.0x
PEG now vs peer median 0.61median 0.43 -1.42median 0.43 -1.47median 0.43

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsLLYJNJPFE
Revenue $86.46B $99.34B $63.63B
Gross profit $72.31B $67.11B $46.69B
Operating income $34.77B $25.19B $19.40B
Net income $27.58B $16.10B $4.06B
Free cash flow $19.66B $20.59B $11.79B
R&D $15.38B $16.08B $11.52B
EPS (diluted) $30.87 $6.57 $0.70
Cash & equivalents $4.89B $16.91B $1.82B
Total debt $49.50B $44.65B $62.67B
Shares (diluted) 893.40M 2.45B 5.75B
Enterprise value $1.25T $601.18B $111.77B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricLLYJNJPFE
P/E 46.7x 42.8x 40.8x
P/FCF 69.2x 33.5x 14.0x
P/Operating cash flow 44.4x 26.3x 11.6x
P/S 15.7x 6.9x 2.6x
P/B 33.8x 8.4x 1.8x
P/Tangible book 61.3x 19.7x 3.8x
EV/EBITDA 38.0x 21.5x 8.2x
EV/EBIT 40.4x 28.4x 11.0x
EV/Revenue 16.2x 7.2x 3.3x
EV/FCF 71.4x 34.8x 18.1x
EV/Operating cash flow 45.8x 27.4x 15.0x
PEG (3Y EPS CAGR) 0.61 -1.42 -1.47

Growth

14 metrics
MetricLLYJNJPFE
Revenue growth (1Y) 45.5% 7.8% 1.3%
Revenue CAGR (3Y) 39.2% -14.5% -3.2%
Gross profit growth (1Y) 46.6% 7.0% 1.3%
Gross profit CAGR (3Y) 42.0% -12.3% 2.7%
Operating income growth (1Y) 48.6% 7.4% -4.3%
Operating income CAGR (3Y) -97.0% -12.8% 7.4%
Net income growth (1Y) 49.8% -35.9% -58.9%
Net income CAGR (3Y) 76.8% -31.0% -27.2%
EPS growth (1Y) 50.7% -36.4% -59.2%
EPS CAGR (3Y) 77.2% -30.1% -27.7%
Operating cash flow growth (1Y) 90.8% 8.1% 8.4%
Operating cash flow CAGR (3Y) 70.2% 11.4% 5.6%
Free cash flow growth (1Y) 124.7% 5.1% 13.6%
Free cash flow CAGR (3Y) 80.6% 8.8% 13.0%

Profitability

14 metrics
MetricLLYJNJPFE
Gross margin 83.6% 67.6% 73.4%
EBITDA margin 42.7% 33.5% 40.7%
Operating margin 40.2% 25.4% 30.5%
Pretax margin 40.2% 17.9% 6.7%
Net margin 31.9% 16.2% 6.3%
FCF margin 22.7% 20.7% 18.5%
Operating cash flow margin 35.4% 26.3% 22.3%
Return on equity 74.4% 19.3% 4.7%
Return on assets 19.0% 8.1% 2.0%
Return on invested capital 30.9% 17.6% 12.3%
Return on capital employed 35.4% 17.5% 11.3%
Asset turnover 0.6x 0.5x 0.3x
Cash conversion (OCF / net income) 1.1x 1.6x 3.5x
Stock comp / revenue 0.8% 1.4% 1.7%

Financial Health

11 metrics
MetricLLYJNJPFE
Debt / assets 33.4% 22.6% 30.6%
Debt / equity 1.2x 0.5x 0.7x
Net debt / EBITDA 1.2x 0.8x 1.9x
Debt / FCF 2.5x 2.2x 5.3x
Liabilities / assets 72.8% 58.7% 56.4%
Equity / assets 27.2% 41.3% 43.6%
Interest coverage – 25.6x –
Current ratio 1.4x 1.0x 1.4x
Quick ratio 0.6x 0.7x 0.9x
Cash ratio 0.1x 0.3x 0.4x
Altman Z-score 9.43 5.69 2.34

Shareholder Returns

7 metrics
MetricLLYJNJPFE
Dividend yield 0.6% 1.8% 6.0%
Net buyback yield 0.4% 0.6% –
Shareholder yield 1.0% 2.4% 6.0%
Payout ratio (earnings) – 79.0% 241.2%
Payout ratio (FCF) – 61.8% 83.1%
Dividend growth (1Y) – 3.9% 0.9%
Dividend CAGR (3Y) – 2.8% 2.2%

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusLLYJNJPFE
Forward P/E 43.1xFY2026 26.7xFY2026 9.8xFY2026
EPS, next fiscal year $33.54FY2026 $10.72FY2026 $2.95FY2026
EPS growth, next FY +38.5%FY2026 -0.6%FY2026 -8.4%FY2026
EPS growth, the year after +46.0% +5.8% -5.8%
Revenue, next fiscal year $87.63BFY2026 $106.55BFY2026 $61.46BFY2026
Revenue growth, next FY +34.4%FY2026 +13.1%FY2026 -1.8%FY2026
Revenue growth, the year after +18.9% +6.8% +4.0%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersLLYJNJPFE
Held by institutions 83.7% 74.7% 66.9%
Institutions holding 4,635 4,699 2,842
Change in shares held, QoQ +1.5% +1.8% +2.0%
Institutions buying 2,636 2,297 1,327
Institutions selling 1,472 1,899 1,206
Buyers to sellers 1.79 1.21 1.10

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

LLYJNJPFE
LLY 1.00 0.47 0.45
JNJ 0.47 1.00 0.33
PFE 0.45 0.33 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, LLY, JNJ and PFE?

Eli Lilly (LLY) is the largest by market capitalisation: Eli Lilly (LLY) $1.28T, Johnson & Johnson (JNJ) $681.31B, Pfizer (PFE) $164.42B.

Which stock is cheaper, LLY, JNJ and PFE?

Pfizer (PFE) trades on the lowest price-to-earnings ratio (Eli Lilly (LLY) 46.3x, Johnson & Johnson (JNJ) 42.3x, Pfizer (PFE) 40.8x). On next year's consensus earnings, Pfizer (PFE) is cheapest (Eli Lilly (LLY) 43.1x, Johnson & Johnson (JNJ) 26.7x, Pfizer (PFE) 9.8x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Eli Lilly (LLY) grew revenue fastest over the trailing twelve months: Eli Lilly (LLY) +45.5%, Johnson & Johnson (JNJ) +7.8%, Pfizer (PFE) +1.3%.

Which company is more profitable?

Eli Lilly (LLY) has the highest net margin (Eli Lilly (LLY) 31.9%, Johnson & Johnson (JNJ) 16.2%, Pfizer (PFE) 6.3%). On return on invested capital, Eli Lilly (LLY) leads (Eli Lilly (LLY) 30.9%, Johnson & Johnson (JNJ) 17.6%, Pfizer (PFE) 12.3%).

Which stock has performed better?

Over the past year Johnson & Johnson (JNJ) returned the most: Eli Lilly (LLY) +41.3%, Johnson & Johnson (JNJ) +46.5%, Pfizer (PFE) +12.1%. Over five years, Eli Lilly (LLY) compounded fastest (Eli Lilly (LLY) +41.0%/yr, Johnson & Johnson (JNJ) +11.6%/yr, Pfizer (PFE) -10.3%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Pfizer (PFE) has the highest dividend yield: Eli Lilly (LLY) 0.00%, Johnson & Johnson (JNJ) 0.02%, Pfizer (PFE) 0.06%. Eli Lilly (LLY) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Johnson & Johnson (JNJ) has been the steadiest (Eli Lilly (LLY) 35.0%, Johnson & Johnson (JNJ) 21.2%, Pfizer (PFE) 21.7%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, LLY, JNJ and PFE?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Eli Lilly (LLY) leads on 6. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.